News Release 

Using cannabinoids to treat acute pain

Mary Ann Liebert, Inc./Genetic Engineering News

IMAGE

IMAGE: The only peer-reviewed journal dedicated to the scientific, medical, and psychosocial exploration of clinical cannabis, cannabinoids, and the biochemical mechanisms of endocannabinoids. view more 

Credit: Mary Ann Liebert, Inc., publishers

New Rochelle, NY, March 23, 2020--A new systematic review and meta-analysis showed a small but significant reduction in subjective pain scores for cannabinoid treatment compared to placebo in patients experiencing acute pain. No increase in serious adverse events suggested the safety of using cannabinoids to treat acute pain, according to the study published in Cannabis and Cannabinoid Research, a peer-reviewed journal from Mary Ann Liebert, Inc., publishers. Click here to read the full-text article free on the Cannabis and Cannabinoid Research website through April 23, 2020.

The article entitled "Cannabinoids in the Management of Acute Pain: A Systematic Review and Meta-analysis" was coauthored by Herman Johal, MD, MPH, PhD, McMaster University, Hamilton, Canada and colleagues from McMaster University and Northern Ontario School of Medicine, Thunder Bay. The researchers included six trials in their study, five using oral cannabinoids, and one using intramuscular cannabinoids. They reported a significant difference in effect size between the oral and nonoral routes of administration, with intramuscular cannabinoids yielding a significant reduction in pain relative to placebo. There was no difference in effect between oral cannabinoids and placebo.

Editor-in-Chief Daniele Piomelli, PhD University of California-Irvine, School of Medicine, states: "The usefulness of cannabis-derived medicines in the treatment of pain, both acute and chronic, is still vigorously debated. The meta-analysis conducted in this study reinforces the need for more rigorous studies to assess whether cannabis might be effective in the treatment of acute pain conditions."

###

About the Journal

Cannabis and Cannabinoid Research is the only peer-reviewed journal dedicated to the scientific, medical, and psychosocial exploration of clinical cannabis, cannabinoids, and the biochemical mechanisms of endocannabinoids. Published quarterly in print and online and led by Editor-in-Chief Daniele Piomelli, PhD, the Journal publishes a broad range of human and animal studies including basic and translational research; clinical studies; behavioral, social, and epidemiological issues; and ethical, legal, and regulatory controversies. Complete tables of content and a sample issue is available on the Cannabis and Cannabinoid Research website.

About the Publisher

Mary Ann Liebert, Inc., publishers is a privately held, fully integrated media company known for establishing authoritative peer-reviewed journals in many promising areas of science and biomedical research, including Journal of Palliative Medicine, The Journal of Alternative and Complementary Medicine, and Journal of Child and Adolescent Psychopharmacology. Its biotechnology trade magazine, GEN (Genetic Engineering & Biotechnology News), was the first in its field and is today the industry's most widely read publication worldwide. A complete list of the firm's 80 journals, books, and newsmagazines is available on the Mary Ann Liebert, Inc., publishers website.

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.